Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome‐Targeted PD‐L1 Degradation
Source abstract
Abstract
ABSTRACT The cGAS‐STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic potential is often limited by the inefficient cytosolic delivery of agonists and the immunosuppressive tumor microenvironment (TME). Here, we report a DNA nanostructure‐based platform that simultaneously induces lysosomal degradation of immune checkpoint protein PD‐L1 and activates the STING pathway. We demonstrate that STING activation further enhances PD‐L1 degradation, resulting in strong synergistic immune activation. In murine models of triple‐negative breast cancer, the DNA nanodevice effectively reprograms the TME by enhancing dendritic cell maturation and CD8 + T cell infiltration, resulting in potent suppression of both primary tumor growth and pulmonary metastases. This study establishes a versatile nanoplatform that bridges targeted protein degradation with STING‐mediated innate immune activation, provides a promise strategy for cancer immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Cancer Immunotherapy and Biomarkers · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Biomedical Sciences State Key Laboratory of Chemo/Bio‐Sensing and Chemometrics College of Chemistry and Chemical Engineering Hunan University Changsha China
School of Physics and Chemistry Hunan First Normal University Changsha China
FuRong Laboratory Changsha China
References (39)
Show source-provided references
1. Cyclic GMP‐AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway10.1126/science.1232458 ↗
2. 10.1038/s41571‐019‐0203‐710.1038/s41571‐019‐0203‐7 ↗
3. 10.1038/s41568‐019‐0116‐x10.1038/s41568‐019‐0116‐x ↗
4. Design of Amidobenzimidazole STING Receptor Agonists with Systemic Activity10.1038/s41586-018-0705-y ↗
5. An Orally Available Non‐nucleotide STING Agonist with Antitumor Activity10.1126/science.aba6098 ↗
6. 10.1016/j.ccell.2025.02.01410.1016/j.ccell.2025.02.014 ↗
7. 10.1038/s41467‐019‐13094‐510.1038/s41467‐019‐13094‐5 ↗
8. 10.1016/j.molcel.2023.09.00710.1016/j.molcel.2023.09.007 ↗
9. The Future of Immune Checkpoint Therapy10.1126/science.aaa8172 ↗
10. An Inflammation‐Targeting Hydrogel for Local Drug Delivery in Inflammatory Bowel Disease
11. 10.1021/jacs.5c0962610.1021/jacs.5c09626 ↗
12. 10.1021/jacs.4c1216610.1021/jacs.4c12166 ↗
13. 10.1021/jacs.5c0514810.1021/jacs.5c05148 ↗
14. Rolling Microneedle Electrode Array (RoMEA) Empowered Nucleic Acid Delivery and Cancer Immunotherapy10.1016/j.nantod.2020.101017 ↗
15. 10.1016/j.ejmech.2018.10.04410.1016/j.ejmech.2018.10.044 ↗
16. Tumor‐targeting Nanocarriers Amplified Immunotherapy of Cold Tumors by STING Activation and Inhibiting Immune Evasion10.1126/sciadv.adr1728 ↗
17. Targeted Degradation of PD‐L1 and Activation of the STING Pathway by Bone‐Targeted Nanoparticles for Enhanced Cancer Immunotherapy10.1002/anie.202218128 ↗
18. Mobilizing STING Pathway via a Cationic Liposome to Enhance Doxorubicin‐Induced Antitumor Immunity10.1002/adfm.202416406 ↗
19. Recent Progress in Solid‐State Lithium Batteries through Cathode Microstructure Engineering10.1002/advs.202513455 ↗
20. 10.1002/adma.20240666210.1002/adma.202406662 ↗
21. Multimodal Lung Cancer Theranostics via Manganese Phosphate/Quercetin Particle10.1186/s12943-025-02242-9 ↗
22. Cancer Immunotherapy Based on the Bidirectional Reprogramming of the Tumor Microenvironment by a “Brakes off/ Step on the Accelerator” Core‐Shell Manganese Phosphate/siPD‐L1 Modulator10.1002/EXP.70009 ↗
23. 10.1021/jacs.4c1470010.1021/jacs.4c14700 ↗
24. 10.1002/anie.20241791610.1002/anie.202417916 ↗
25. 10.1021/jacs.2c0897410.1021/jacs.2c08974 ↗
26. 10.1016/j.bbagen.2011.09.00910.1016/j.bbagen.2011.09.009 ↗
27. 10.1038/s41586‐024‐07947‐310.1038/s41586‐024‐07947‐3 ↗
28. CYpHER: Catalytic Extracellular Targeted Protein Degradation with High Potency and Durable Effect10.1038/s41467-024-52975-2 ↗
29. 10.1038/ni.326710.1038/ni.3267 ↗
30. Nonviolent Self‐catabolic DNAzyme Nanosponges for Smart Anticancer Drug Delivery10.1021/acsnano.9b01589 ↗
31. 10.1016/j.immuni.2024.11.01710.1016/j.immuni.2024.11.017 ↗
32. 10.1038/s41598‐021‐86644‐x10.1038/s41598‐021‐86644‐x ↗
33. 10.1002/anie.20210217010.1002/anie.202102170 ↗
34. 10.1021/jacs.3c0888610.1021/jacs.3c08886 ↗
35. Covalent LYTAC Enabled by DNA Aptamers for Immune Checkpoint Degradation Therapy
36. NOD‐like Receptors in Autoimmune Diseases10.1038/s41401-020-00603-2 ↗
37. 10.1038/s41423‐020‐00602‐710.1038/s41423‐020‐00602‐7 ↗
38. Radiotherapy and Immunotherapy Converge on Elimination of Tumor‐Promoting Erythroid Progenitor Cells through Adaptive Immunity10.1126/scitranslmed.abb0130 ↗
39. 10.1126/scitranslmed.abb013010.1126/scitranslmed.abb0130 ↗